Promotiom G. Vondeling

Redefining value in breast cancer

Breast cancer remains one of the most common cancers worldwide. New treatments keep pushing survival further, but they also come with steep price tags that spark public debate. This PhD research by Gert Vondeling looks at what really counts as "value" when it comes to new cancer drugs, beyond just their price or how long they help patients live.

Vondeling shows that a large and still-growing group of patients, those with so-called "HER2-low" breast cancer, were long overlooked by both science and health insurers, even though they can benefit from newer treatments. He also shows, through direct interviews with patients, that people don't only care about survival: things like fewer side effects and easier, less invasive treatment matter just as much to them. Finally, the research tracks what happens to drug prices over time, showing that today's expensive cancer drugs typically become dramatically cheaper once patents expire and cheaper copies enter the market. This is a pattern that should factor into today's pricing debates. 

Together, the findings argue for a broader, fairer way of judging what a cancer drug is really worth: one that looks beyond the price tag at launch.

Find the full thesis here: Redefining value in breast cancer: Health economic frameworks, innovation dynamics, and implications for patient access